卵巢癌免疫治疗进展

Advances in immunotherapies in ovarian cancer.

化疗驱动的高级别浆液性卵巢癌中 NK 细胞受体和配体的改变

Chemotherapy driven alterations in NK cell receptors and ligands in high grade serous ovarian cancer.

我们的发现凸显了化疗对 NK 细胞受体、配体和细胞因子的广泛免疫调节作用，这可能为 HGSOC 的联合治疗提供见解。

CAR-T 与 CAR-NK 细胞疗法治疗卵巢癌的当前进展

Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.

基于生物信息学分析的卵巢癌 CAR-T 治疗差异表达蛋白发现

Discovery of differentially expressed proteins for CAR-T therapy of ovarian cancers with a bioinformatics analysis.

开发患者来源 3D 免疫肿瘤学平台以增强腹水来源循环肿瘤细胞的免疫治疗应答

Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells.

MACSima 成像循环染色 (MICS) 技术揭示用于实体瘤 CAR-T 细胞治疗的组合靶点对

MACSima imaging cyclic staining (MICS) technology reveals combinatorial target pairs for CAR T cell treatment of solid tumors.

鉴定用于卵巢癌细胞免疫治疗的 Claudin 6 特异性 HLA I 类和 HLA II 类限制性 T 细胞受体

Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.